20

CLAIMS

- 1. An isolated polynucleotide encoding a polypeptide that comprises the amino acid sequence shown in SEQ ID NO:2.
- 2. The isolated polynucleotide of claim 1 which comprises the nucleotide sequence shown in SEQ ID NO:1.
 - 3. The isolated polynucleotide of claim 1 which consists of the nucleotide sequence shown in SEQ ID NO:1.
 - 4. The isolated polynucleotide of claim 1 which is a cDNA molecule.
- 5. An expression vector comprising a polynucleotide that encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
 - 6. The expression vector of claim 5 which comprises the nucleotide sequence shown in SEQ ID NO:1.
 - 7. A host cell comprising an expression vector comprising a polynucleotide that encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
 - 8. The host cell of claim 7 wherein the expression vector comprises the nucleotide sequence shown in SEQ ID NO:1.
 - 9. A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
 - 10. The purified polypeptide of claim 9 which consists of the amino acid sequence of SEQ ID NO:2.
 - 11. A fusion protein comprising a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:2.
- 12. A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:

culturing a host cell comprising an expression vector that comprising the nucleotide sequence shown in SEQ ID NO:1 under conditions whereby the polypeptide is expressed; and

15

20

25

isolating the polypeptide.

13. A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:

hybridizing to nucleic acid material of a biological sample a polynucleotide comprising 11 contiguous nucleotides of the complement of the nucleotide sequence shown in SEQ ID NO:1, thereby forming a hybridization complex; and

detecting the hybridization complex.

- 14. The method of claim 13 further comprising the step of amplifying the nucleic acid material before the step of hybridizing.
 - 15. A kit for detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising:
 - a polynucleotide comprising 11 contiguous nucleotides of the complement of the nucleotide sequence shown in SEQ ID NO:1; and

instructions for the method of claim 13.

16. A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:

contacting a biological sample with an antibody that specifically binds to the polypeptide to form a reagent-polypeptide complex; and

detecting the reagent-polypeptide complex.

17. A kit for detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising:

an antibody that specifically binds to the polypeptide; and instructions for the method of claim 16.

18. A method of screening for agents that can regulate the activity of an neuropeptide Y-like G protein-coupled receptor (NPY-like GPCR), comprising the steps of:

contacting a test compound with a polypeptide comprising the amino

02973.00040 405552 5058

5

acid sequence shown in SEQ ID NO:2; and

detecting binding of the test compound to the polypeptide, wherein a test compound that binds to the polypeptide is identified as a potential agent for regulating activity of the NPY-like GPCR.

- 19. The method of claim 20 wherein the step of contacting is in a cell.
 - 20. The method of claim 20 wherein the step of contacting is *in vitro*.
 - 21. The method of claim 20 wherein the step of contacting is in a cell-free system.
- 22. The method of claim 20 wherein the first polypeptide comprises a detectable label.
 - 23. The method of claim 20 wherein the test compound comprises a detectable label.
 - 24. The method of claim 20 wherein the test compound displaces a ligand that is bound to the NPY-like GPCR.
- The method of claim 20 wherein the first polypeptide is bound to a solid support.
 - 26. The method of claim 20 wherein the test compound is bound to a solid support.
- 27. A method of screening for agents that can regulate the activity of an NPY-like GPCR, comprising the steps of:

contacting a test compound with a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:1; and

detecting binding of the test compound to the product, wherein a test compound that binds to the product is identified as a potential agent for regulating the activity of the NPY-like GPCR.

- 28. The method of claim 27 wherein the product is a polypeptide.
- 29. The method of claim 27 wherein the product is RNA.
- 30. A method of reducing expression of an NPY-like GPCR, comprising the

02973.00040 405552 5058

step of:

5

contacting a cell with an antibody that specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, whereby expression of the NPY-like GPCR is reduced.

- 31. The method of claim 30 wherein the cell is *in vivo*.
 - 32. The method of claim 30 wherein the cell is *in vitro*.
 - 33. A method of reducing expression of an NPY-like GPCR, comprising the step of:

contacting a cell with an antisense oligonucleotide that specifically binds to a the nucleotide sequence shown in SEQ ID NO:1, whereby expression of the NPY-like GPCR is reduced.

- 34. The method of claim 33 wherein the cell is *in vivo*.
- 35. The method of claim 33 wherein the cell is *in vitro*.
- 36. A pharmaceutical composition, comprising:
- an antibody that specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2; and

a pharmaceutically acceptable carrier.

- 37. A pharmaceutical composition, comprising:
- an antisense oligonucleotide that specifically binds to the nucleotide sequence shown in SEQ ID NO:1; and

a pharmaceutically acceptable carrier.

- 38. A pharmaceutical composition, comprising:
- an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2; and
- a pharmaceutically acceptable carrier.
 - 39. The pharmaceutical composition of claim 38 wherein the expression vector comprising the nucleotide sequence shown in SEQ ID NO:1.
 - 40. A method of treating obesity comprising the steps of:

02973.00040 405552 5058 administering to a patient in need thereof a therapeutically effective dose of a reagent that regulates expression of the NPY-like GPCR, whereby symptoms of the obesity are ameliorated.

- 41. An antibody that specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
 - 42. The antibody of claim 41 which is monoclonal.
 - 43. The antibody of claim 1 which is polyclonal.